Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
15654-1-PBS targets ST6GALNAC4 in IP, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | ST6GALNAC4 fusion protein Ag7995 相同性解析による交差性が予測される生物種 |
| Full Name | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 |
| Calculated molecular weight | 34 kDa |
| Observed molecular weight | 35 kDa |
| GenBank accession number | BC036705 |
| Gene Symbol | ST6GALNAC4 |
| Gene ID (NCBI) | 27090 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9H4F1 |
| Storage Buffer | PBS only , pH 7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
Alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide alpha-2,6-sialyltransferase (also known as ST6GALNAC4) is a member of the sialyltransferases, which catalyzes the transfer of sialic acid from cytidine monosphosphate (CMP)-sialic acid to galactose-containing substrates. ST6GALNAC4 may be induced abnormal TGFBR2 glycosylation, resulting in the higher protein levels of TGFBR2 and TGF pathway increased activation (PMID: 37381011, 37034303). ST6GALNAC4 was reported to influence patient prognosis though subverting immunosurveillance in Chronic lymphocytic leukemia.